Concord Drugs Limited announced earnings results for the fourth quarter ended March 31, 2021. For the fourth quarter, the company announced total revenue was INR 83.6784 million compared to INR 130.7373 million a year ago. Net income was INR 3.3567 million compared to INR 1.172 million a year ago. Basic earnings per share from continuing operations was INR 0.38 compared to INR 0.13 a year ago. For the full year, total revenue was INR 514.516 million compared to INR 514.589 million a year ago. Net income was INR 32.817 million compared to INR 3.283 million a year ago. Basic earnings per share from continuing operations was INR 3.75 compared to INR 0.38 a year ago.